A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
- 1 June 1996
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 347 (9014) , 1523-1527
- https://doi.org/10.1016/s0140-6736(96)90674-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patientsInternational Journal of Gynecologic Cancer, 1995
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Prophylactic and therapeutic vaccination against a mucosal papillomavirusJournal of General Virology, 1993
- Expression of human papillomavirus type 16 E7 protein by recombinant baculovirus and use for the detection of E7 antibodies in sera from cervical carcinoma patientsJournal of Medical Virology, 1993
- Definition of human papillomavirus type 16 DNA levels in low and high grade cervical lesions by a simple polymerase chain reaction techniqueArchiv für die gesamte Virusforschung, 1993
- Expression of human papillomavirus type 16 E6 protein by recombinant baculovirus and use for detection of anti-E6 antibodies in human seraJournal of General Virology, 1992
- Human cytotoxic T cell responses to vaccinia virus vaccinationJournal of General Virology, 1991
- Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses.The Journal of Experimental Medicine, 1988
- Estimates of the worldwide frequency of sixteen major cancers in 1980International Journal of Cancer, 1988
- Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) DiseaseNew England Journal of Medicine, 1987